中枢神经系统（CNS）治疗市场规模、份额和成长分析（按疾病、药物类别、通路和地区划分）－2026-2033年产业预测

预计到 2024 年，中枢神经系统 (CNS) 治疗市场规模将达到 1,449.6 亿美元，到 2025 年将达到 1,540.9 亿美元，到 2033 年将达到 2,512.2 亿美元，预测期（2026-2033 年）的复合年增长率为 6.3%。

中枢神经系统（CNS）治疗市场是医疗保健和製药行业的重要组成部分，为神经系统和精神疾病提供广泛的治疗方案。随着人们对中枢神经系统复杂性的认识不断加深，以及对心理健康挑战日益关注和人口老化带来的持续创新，推动了该领域的成长。製药公司和研究机构之间的合作正在推动治疗方法的进步。儘管该市场具有显着改善患者生活品质的潜力，但也面临监管核准流程、定价趋势和竞争压力等挑战。相关人员必须制定策略，应对这些挑战，才能最大限度地掌握这个不断发展的市场所带来的机会。

中枢神经系统（CNS）治疗市场驱动因素

全球人口老化导致阿兹海默症和帕金森氏症等神经系统疾病的发生率显着上升。由于老年人更容易患上这些疾病，这种人口结构变化显着增加了对中枢神经系统的治疗方案的需求。因此，这些疾病盛行率的不断上升推动了对先进的中枢神经系统治疗方法和创新疗法的需求，凸显了有效医疗干预措施以满足日益增长的患者群体需求的紧迫性。解决神经系统健康问题至关重要，因为它与提高老年人生活品质的更广泛目标相契合。

中枢神经系统（CNS）治疗市场限制因素

由于用于治疗神经和精神疾病的药物研发过程漫长，中枢神经系统（CNS）治疗市场面临严峻的挑战。全面的临床试验和严格的监管审查往往导致研发延误，并加重企业的财务负担。这些障碍阻碍了创新，使得新治疗方法难以快速上市。因此，监管合规的复杂性可能会延缓突破性CNS疗法的研发和核准，这可能会减少患者获得有效治疗的机会。

中枢神经系统（CNS）药物市场趋势

随着基因和神经影像技术的进步，人们对中枢神经系统（CNS）疾病的个体差异有了更深入的了解，CNS治疗市场正加速向个人化医疗转型。这一趋势着重于根据患者特定的基因组成、神经生物学特征和治疗反应来定制治疗策略，从而实现更精准有效的干预。因此，个人化医疗可望改变阿兹海默症、忧郁症和思觉失调症等常见疾病的治疗模式，最终改善患者预后，并推动CNS治疗领域的成长。这种变革有望提高疗效，减少副作用，从而在神经病学领域建立一种更以患者为中心的治疗方法。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球中枢神经系统（CNS）治疗市场规模（按疾病和复合年增长率划分）（2026-2033 年）

• 神经血管疾病
• 中枢神经系统创伤
• 心理健康
  • 焦虑症
  • 癫痫
  • 情绪障碍
  • 精神病性障碍
  • 其他的
• 神经退化性疾病
  • 阿兹海默症
• 帕金森氏症
  • 多发性硬化症
  • 亨丁顿舞蹈症
• 肌萎缩侧索硬化症
  • 其他的
• 感染疾病
• 中枢神经系统癌症
• 其他的

全球中枢神经系统（CNS）治疗药物市场规模（按药物类别和复合年增长率划分）（2026-2033 年）

• 麻醉剂
• 抗惊厥药
• 止吐药
• 中枢神经系统兴奋剂
• 止痛药
• 其他的

全球中枢神经系统（CNS）治疗药物市场规模（按通路划分）及复合年增长率（2026-2033 年）

• 医院药房
• 零售药房
• 其他的

全球中枢神经系统（CNS）治疗市场规模（按地区划分）及复合年增长率（2026-2033 年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Biogen（United States）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Eli Lilly and Company（United States）
• Merck & Co., Inc.（United States）
• AstraZeneca（United Kingdom）
• Takeda Pharmaceutical Company Limited（Japan）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Johnson & Johnson Services, Inc.（United States）
• Pfizer Inc.（United States）
• Sanofi SA（France）
• H. Lundbeck A/S（Denmark）
• UCB SA（Belgium）
• PTC Therapeutics（United States）
• Jazz Pharmaceuticals plc（Ireland）
• Acadia Pharmaceuticals, Inc.（United States）
• Neumora Therapeutics（United States）
• Immunic Therapeutics（United States）
• Muna Therapeutics（Denmark）
• NRG Therapeutics（United Kingdom）

结论与建议

CNS (Central Nervous System) Therapeutics Market size was valued at USD 144.96 Billion in 2024 and is poised to grow from USD 154.09 Billion in 2025 to USD 251.22 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).

The Central Nervous System (CNS) Therapeutics market represents a vital segment of the healthcare and pharmaceutical landscape, offering a myriad of treatments for neurological and psychiatric disorders. As the complexities of the CNS are increasingly understood, the sector benefits from continuous innovation driven by heightened awareness of mental health challenges and a growing elderly population. Collaborative efforts between pharmaceutical companies and research organizations are propelling advancements in therapeutic methods. While the market showcases potential for significantly enhancing the quality of life for affected individuals, it also encounters hurdles such as regulatory approval processes, pricing dynamics, and competitive pressures. Stakeholders must strategically navigate these challenges to capitalize on the opportunities presented within this evolving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the CNS (Central Nervous System) Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

CNS (Central Nervous System) Therapeutics Market Segments Analysis

Global CNS (Central Nervous System) Therapeutics Market is segmented by Disease, Drug Class, Distribution Channel and region. Based on Disease, the market is segmented into Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer and Others. Based on Drug Class, the market is segmented into Anesthetics, Anticonvulsants, Antiemetics, CNS Stimulants, Pain Relievers and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the CNS (Central Nervous System) Therapeutics Market

The increasing aging population globally contributes to a notable rise in the incidence of neurological disorders, such as Alzheimer's and Parkinson's disease. This demographic transition significantly enhances the need for therapeutic solutions targeting the central nervous system, as the elderly are more vulnerable to these ailments. Consequently, the growing prevalence of these disorders drives the demand for advanced CNS therapies and innovative treatments, highlighting the urgency for effective medical interventions tailored to meet the needs of this expanding patient population. The focus on addressing neurological health is paramount, as it aligns with the broader goal of improving quality of life among aging individuals.

Restraints in the CNS (Central Nervous System) Therapeutics Market

The CNS Therapeutics market faces significant challenges due to the lengthy process of developing drugs for neurological and psychiatric conditions. The necessity for comprehensive clinical trials and the strict evaluations by regulatory bodies often result in delays and increased financial burdens for companies. These obstacles can stifle innovation, making it more difficult to introduce new therapies promptly. Consequently, patient access to effective treatments may be adversely affected, as the complexities of regulatory compliance slow down the development and approval of potentially life-changing therapeutics in the Central Nervous System sector.

Market Trends of the CNS (Central Nervous System) Therapeutics Market

The Central Nervous System (CNS) therapeutics market is increasingly leaning towards personalized medicine, driven by advancements in genetics and neuroimaging technologies that enhance the understanding of individual variations in CNS disorders. This trend focuses on customizing treatment strategies based on a patient's specific genetic makeup, neurobiological characteristics, and therapeutic responses, promoting more precise and effective interventions. As a result, personalized approaches are expected to transform the treatment paradigm for prevalent conditions such as Alzheimer's disease, depression, and schizophrenia, ultimately improving patient outcomes and driving growth within the CNS therapeutics sector. This evolution can lead to better efficacy and reduced side effects, shaping a more patient-centered approach in neurology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global CNS (Central Nervous System) Therapeutics Market Size by Disease & CAGR (2026-2033)

• Market Overview
• Neurovascular Diseases
• CNS Trauma
• Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Mood Disorders
  • Psychotic Disorders
  • Others
• Neurodegenerative Diseases
  • Alzheimer's Disease
• Parkinson's Disease
  • Multiple Sclerosis
  • Huntington's Disease
• Amytrophic Lateral Sclerosis
  • Others
• Infectious Diseases
• CNS Cancer
• Others

Global CNS (Central Nervous System) Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Anesthetics
• Anticonvulsants
• Antiemetics
• CNS Stimulants
• Pain Relievers
• Others

Global CNS (Central Nervous System) Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global CNS (Central Nervous System) Therapeutics Market Size & CAGR (2026-2033)

• North America (Disease, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Disease, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Biogen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neumora Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunic Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Muna Therapeutics (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NRG Therapeutics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations